MMAB: A Potential Drug Target and Biomarker for Type 2 Diabetes

Target Name: MMAB

NCBI ID: G326625

MMAB

MMAB: A Potential Drug Target and Biomarker for Type 2 Diabetes

Metformin is one of the most widely used anti-diabetic drugs, which has been shown to improve quality of life and reduce the risk of cardiovascular events in patients with type 2 diabetes. It works by inhibiting the enzyme ATP:cob(I)alamin adenosyltransferase (MMAB), which is an essential enzyme in the Uptake of Adenosine (Ado) in the body. In this article, we will discuss the potential implications of MMAB as a drug target or biomarker for the treatment of type 2 diabetes and other related conditions.

The Importance of Adenosine

Adenosine is a naturally occurring molecule that plays a crucial role in various physiological processes in the body, including muscle relaxation, blood pressure regulation, and immune function. It is also involved in the regulation of pain and inflammation. However, abnormally high levels of adenosine can lead to a variety of health problems, including cardiovascular disease, neurodegenerative diseases, and certain cancers.

ATP:cob(I)alamin adenosyltransferase (MMAB) Enzyme

ATP:cob(I)alamin adenosyltransferase (MMAB) is an enzyme that is responsible for the uptake of adenosine in the body. It is a key enzyme in the AdoA+-dependent intracellular signaling pathway, which is involved in the regulation of various cellular processes, including inflammation, pain, and sleep.

MMAB is composed of two subunits, alpha and beta subunits, which are located on the surface of the cell and interact with each other to facilitate the uptake of adenosine. The alpha subunit is responsible for the conversion of adenosine to its active form, while the beta subunit is responsible for the uptake of adenosine into the cell.

MMAB is regulated by various factors, including blood flow, neurotransmitters, and signaling pathways. It is also influenced by genetic factors, which can affect its expression and activity.

MMAB as a Drug Target

The potential use of MMAB as a drug target or biomarker for the treatment of type 2 diabetes and other related conditions is due to its involvement in the regulation of adenosine and its impact on various cellular processes.

1. Improved Insulin Sensitivity: Insulin resistance is a major risk factor for the development and progression of type 2 diabetes. It is characterized by an increase in the resistance of insulin to insulin action, which can lead to an increase in blood sugar levels.MMAB has been shown to improve insulin sensitivity in various cell lines and animal models of type 2 diabetes.
2. Reduced inflammation: MMAB has been shown to reduce inflammation in various cellular models of inflammation, including the liver and muscle. This may have implications for the treatment of neurodegenerative diseases and certain cancers.
3. Improved pain relief: MMAB has been shown to reduce pain in various animal models of pain, including neuropathic pain. This may have implications for the treatment of chronic pain conditions.
4. Cardiovascular protection: MMAB has been shown to improve cardiovascular health in various animal models, including the regulation of blood pressure and cholesterol levels. This may have implications for the treatment of cardiovascular disease.

MMAB as a Biomarker

MMAB can also be used as a biomarker for the diagnosis and monitoring of various diseases, including type 2 diabetes. The levels of MMAB have been shown to be affected by various factors, including blood flow, neurotransmitters, and signaling pathways. This may provide a sensitive and reliable biomarker for the assessment of disease status and response to therapeutic interventions.

Conclusion

In conclusion, ATP:cob(I)alamin adenosyltransferase (MMAB) is an essential enzyme in the regulation of adenosine and its impact on various cellular processes. The potential use of MMAB as a drug target or biomarker for the treatment of

Protein Name: Metabolism Of Cobalamin Associated B

Functions: Converts cob(I)alamin to adenosylcobalamin (adenosylcob(III)alamin), a coenzyme for methylmalonyl-CoA mutase, therefore participates in the final step of the vitamin B12 conversion (PubMed:12514191). Generates adenosylcobalamin (AdoCbl) and directly delivers the cofactor to MUT in a transfer that is stimulated by ATP-binding to MMAB and gated by MMAA (Probable)

The "MMAB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MMAB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets